Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2018
Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Lawrence L'Italien, Olivia Orozco, Tinya Abrams, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors
Michael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Biopolymers
|
October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitors
Thierry O Fischmann, Alan Hruza, José S Duca, et al.
Cancer Immunology Research
|
August 28, 2019
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression
Ali Roghanian, Guangan Hu, Christopher Fraser, et al.
Journal of Molecular Biology
|
December 15, 2010
A structural model for apolipoprotein C-II amyloid fibrils: experimental characterization and molecular dynamics simulations
Chai Lean Teoh, Chi L L Pham, Nevena Todorova, et al.
Science Translational Medicine
|
October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity
Michael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
Tinya Abrams, Anu Connor, Christie Fanton, et al.
Cancer Research
|
January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Wenlin Shao, Yuji M Mishina, Yun Feng, et al.
Molecular Cancer Therapeutics
|
August 28, 2020
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies
Haihui Lu, Ryan D Molony, Dongshu Chen, et al.
Journal for Immunotherapy of Cancer
|
January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You, Stephen Hillerman, Gregory Locke, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2018
Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Lawrence L'Italien, Olivia Orozco, Tinya Abrams, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors
Michael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Biopolymers
|
October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitors
Thierry O Fischmann, Alan Hruza, José S Duca, et al.
Cancer Immunology Research
|
August 28, 2019
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression
Ali Roghanian, Guangan Hu, Christopher Fraser, et al.
Journal of Molecular Biology
|
December 15, 2010
A structural model for apolipoprotein C-II amyloid fibrils: experimental characterization and molecular dynamics simulations
Chai Lean Teoh, Chi L L Pham, Nevena Todorova, et al.
Science Translational Medicine
|
October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity
Michael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
Tinya Abrams, Anu Connor, Christie Fanton, et al.
Cancer Research
|
January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Wenlin Shao, Yuji M Mishina, Yun Feng, et al.
Molecular Cancer Therapeutics
|
August 28, 2020
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies
Haihui Lu, Ryan D Molony, Dongshu Chen, et al.
Journal for Immunotherapy of Cancer
|
January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You, Stephen Hillerman, Gregory Locke, et al.
Page
of 4